Skip to main content
Equibles

CL · Cresco Labs Inc.

Use CL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
0.7900 CAD +0.0000 (+0.00%) At close · Nov 6 Intraday price with Plus
Rebalance outlook locked

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close0.7900 CAD Open0.7900 CAD Day0.7900–0.8200 CAD 52W close0.7900–2.7200 CAD Avg vol 30d84K Last earningsNov 6, 2026 DataJan 2020–Nov 2026

Latest documents

2026
Nov 6
Earnings call
Revenue rose 5% as free cash flow reached $21 million

Cresco Labs reported third-quarter 2026 revenue of $173 million, up 5% year-over-year, adjusted EBITDA of $35 million and free cash flow of $21 million after acquiring nine Pennsylvania dispensaries.

3 source passages
Good morning, everyone, and thank you for joining Cresco Labs' third quarter 2026 earnings call. We generated $173 million in revenue, up 5% year-over-year. We produced $81 million in adjusted gross profit. We produced $35 million in adjusted EBITDA, resulting in a 20% margin. And we generated $26 million in operating cash flow, up from $15 million in Q2, and $21 million in free cash flow. On September 2nd, we closed the acquisition of the nine Pennsylvania dispensaries, a state where our scaled position gives us operating leverage. Open the document at this passage
Nov 6
Current report 6-K
Revenue rose as net loss narrowed

Cresco Labs reported revenue of 172,782 for the three months ended September 30, 2026 versus 164,913 in 2025, while net loss narrowed to (14,533) from (21,968), in thousands of United States Dollars.

Read from the first part of this long document
4 source passages
Cresco Labs Inc. Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss For the Three and Nine Months Ended September 30, 2026 and 2025 (In thousands of United States Dollars, except share and per share amounts) Revenues, net | 172,782 | 164,913 | 497,448 | 494,294 Net loss | (14,533) | (21,968) | (16,178) | (51,095) Open the document at this passage
All documents

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its 52-week range
Range low 0.7900 CAD Now 0.7900 CAD · 0% Range high 2.7200 CAD
vs 200-day avg -33% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XCNQ:CL -1.3% -14.1% -29.5% -1.3% -52.4%

Exchange listing

Market
XCNQ
Ticker
CL
ISIN
—
Security
Ordinary share
Trading currency
CAD

Company with tickers: CRLBF

Company

Website
https://www.crescolabs.com/
Investor relations
https://investors.crescolabs.com/overview/default.aspx

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Latest price

Plus & Pro

Follow CL during the session: the latest price, the day's change, range and volume. Closing prices stay free.

View plans Sign in

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q3 2026 2026-11-06 Audio Transcript
    Cresco Labs to Report Third Quarter 2026 Financial Results on November 6, 2026
  • Earnings call · Q2 2026 2026-08-06 Audio Transcript
    Cresco Labs Second Quarter 2026 Earnings Conference Call
  • Earnings call · Q1 2026 2026-05-08 Audio Transcript
    Cresco Labs First Quarter 2026 Earnings Conference Call
  • Earnings call · Q4 2025 2026-03-05 Audio Transcript
    Cresco Labs Fourth Quarter 2025 Earnings Conference Call